Head-To-Head Contrast: Chugai Pharmaceutical (OTCMKTS:CHGCY) & Vivos Therapeutics (NASDAQ:VVOS)

Chugai Pharmaceutical (OTCMKTS:CHGCY) and Vivos Therapeutics (NASDAQ:VVOS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, dividends, analyst recommendations, institutional ownership, valuation and profitability.

Volatility & Risk

Chugai Pharmaceutical has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 6.16, meaning that its stock price is 516% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Chugai Pharmaceutical and Vivos Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chugai Pharmaceutical	0	1	1	2	3.25
Vivos Therapeutics	1	1	2	0	2.25

Vivos Therapeutics has a consensus target price of $2.80, indicating a potential upside of 520.84%. Given Vivos Therapeutics’ higher possible upside, analysts clearly believe Vivos Therapeutics is more favorable than Chugai Pharmaceutical.

Institutional & Insider Ownership

0.0% of Chugai Pharmaceutical shares are owned by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are owned by institutional investors. 2.1% of Vivos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Chugai Pharmaceutical and Vivos Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Chugai Pharmaceutical	34.98%	22.90%	19.45%
Vivos Therapeutics	-127.70%	-2,325.64%	-98.12%

Valuation and Earnings

This table compares Chugai Pharmaceutical and Vivos Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chugai Pharmaceutical	$8.41 billion	9.25	$2.91 billion	$0.90	26.27
Vivos Therapeutics	$17.44 million	0.36	-$21.17 million	($2.14)	-0.21

Chugai Pharmaceutical has higher revenue and earnings than Vivos Therapeutics. Vivos Therapeutics is trading at a lower price-to-earnings ratio than Chugai Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Summary

Chugai Pharmaceutical beats Vivos Therapeutics on 10 of the 15 factors compared between the two stocks.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

About Vivos Therapeutics

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.